Novo Nordisk plans $2 billion investment in new production facilities in Clayton, North Carolina and Måløv, Denmark
Novo Nordisk plans to invest an estimated 2 billion US dollars over the next 5 years in new production facilities in Clayton, North Carolina, US and Måløv, Denmark. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines.
The copany has also announced a decision to initiate Phase IIIa development of oral semaglutide, a GLP-1 analogue formulated as a once-daily tablet for the treatment of type 2 diabetes. The facilities in Clayton will produce APIs for both oral semaglutide and a range of Novo Nordisk's current and future GLP-1 and insulin products.
The investment is estimated to create close to 700 new production and engineering jobs in Clayton where Novo Nordisk already employs more than 700 people.
Novo Nordisk also plans to establish a new production facility in Måløv, Denmark for tableting and packaging of oral semaglutide and future oral products. The investment in Måløv will create an estimated 100 new jobs.
"With the new plant in Clayton and continuous investments in our current API production plants in Kalundborg, Denmark, we will have sufficient API capacity for diabetes products well into the next decade," says Henrik Wulff, executive vice president and head of Product Supply at Novo Nordisk.
"We decided to place the new API facilities in the US for strategic reasons," adds Henrik Wulff. "The US is by far our largest market and there are many logistical and economic advantages of having a larger part of our manufacturing in our main market. After a thorough evaluation of multiple sites and an extensive vetting process, Clayton ended up being our preferred location. We already have a large and very professional organisation there and an excellent collaboration with city, local and state leadership, and we appreciate the incentives they have secured in connection with this investment."
The final design and cost of the new production facilities will be presented for approval by the company's board of directors in 2016. The facilities are expected to be operational during 2020.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance